ZBIO: Obexelimab nears FDA review with strong market potential and pivotal data readouts ahead
Multiple late-stage programs are advancing, with obexelimab under FDA review and key data readouts expected in the coming quarters. Market research suggests strong commercial potential in IgG4-RD, and the company is expanding its pipeline in autoimmune and neuroimmunology indications.Based on Zenas…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.